US EditionLong Shortz with Island Pharma: Targeting Ebola, Zika & Marburg with Gallidesivir
Summary by Stockhead
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Long Shortz with Island Pharma: Targeting Ebola, Zika & Marburg with Gallidesivir
Tylah Tully chats with Island Pharmaceuticals (ASX:ILA) managing director Dr David Foster after the company expanded its antiviral portfolio with the acquisition of the Galidevsivir program from NASDAQ-listed BioCryst Pharmaceuticals. The broad-spectrum drug targets deadly viruses like Ebola, Marburg, and Zika, and Island plans to pursue FDA approval under the “animal rule” pathway -potentially making it just one animal study away from filing a…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
